# CIMPLRX

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/cimplrx

- Industry: Biotechnology
- Headquarters: Anyang-si, South Korea
- Website: www.cimplrx.com/
- Total disclosed funding: $4.2M
- Latest round: Series A (Jun 30, 2020)
- Investors on record: 3

## About

CIMPLRX, based in South Korea, is a biotechnology company focused on drug discovery and development utilizing its proprietary Explainable Artificial Intelligence platform, CEEK-CURE, to enhance the drug development process for pharmaceutical and biotech companies.Founded in 2017 and headquartered in Anyang, South Korea, CIMPLRX operates in the biotechnology sector, specializing in innovative solutions for drug discovery. The company raised KRW 5 billion in Series A funding on June 30, 2020, with investors including Atinum Investment, Company K Partners, and Korea Asset Investment & Securities. The founder’s history includes prior experience in starting and managing biotechnology ventures, although specific details of other companies are not disclosed.CIMPLRX specializes in drug discovery and development through its proprietary Explainable Artificial Intelligence (XAI) platform, CEEK-CURE. This platform consists of two main components: Create ExplainablE Knowledge (CEEK), which provides a user interface for data analysis, and Collect and Uncover RElationships (CURE), which processes various user requests on the server side. The platform uses Uniprot IDs to identify compounds related to biological targets, enabling the creation of predictive models that assist pharmaceutical companies and biotech firms in designing drug candidates and screening commercial databases. Notable clients include Bristol-Myers Squibb and Amgen, with operations primarily in North America, Europe, and Asia.CIMPLRX's revenue model primarily relies on collaborations with pharmaceutical and biotechnology companies, typically involving project-based agreements for drug discovery initiatives. The company engages in direct B2B transactions, offering its CEEK-CURE platform as a service. These partnerships allow clients access to advanced predictive models and tools that optimize drug development. While specific pricing structures are not disclosed, transactions are generally based on fixed project fees or subscription models, which support CIMPLRX's ongoing innovation in drug discovery.Looking ahead, CIMPLRX aims to enhance its CEEK-CURE platform with new features and predictive models tailored for drug discovery, although specific launch dates for these developments have not been announced. The company is also planning to expand its presence in European markets by 2023. The recent Series A funding of KRW 5 billion will be utilized to support these growth initiatives, including the enhancement of their AI capabilities and market expansion efforts.

## Funding rounds

- Series A, Jun 30, 2020, $4.2M — Atinum Investment, Company K Partners, Korea Asset Investment & Securities

## Investors

- Atinum Investment (https://capitalatlas.ai/funds/atinum-investment) — Series A
- Company K Partners (https://capitalatlas.ai/funds/company-k-partners) — Series A
- Korea Asset Investment & Securities — Series A